The Management Board of Krka, d. d. presented the preliminary unaudited performance estimate for 2025 at a press conference, following discussion by the Supervisory Board. The company reported that the Krka Group generated €2,041.0 million in revenue for 2025, an increase of €131.5 million or 7% compared to 2024. Earnings before interest, tax, depreciation and amortisation (EBITDA) reached €559.1 million, representing 27.4% of total revenue. Net profit is projected at €401.1 million, up 13% from the previous year.
Jože Colarič, President of the Management Board and Chief Executive Officer, commented: “This past year was a successful one. We have marked a notable milestone, outstripping €2 billion in revenue for the first time in history, and saw sales grow in most our markets, the highest in Region East Europe.
We are aware that long-term sales growth also depends on extension of the product portfolio, so we added 17 new products to it, and completed more than 900 marketing authorisation procedures for new and established products in various markets. Most of them are used for treating chronic cardiovascular and central nervous system diseases, gastrointestinal disorders, diabetes, and pain relief. They also include new combination medicines, which are gaining an ever more prominent share in Krka sales.
Sales growth led to increased profitability. We recorded estimated operating profit (EBIT) of €465.6 million, up 9%, and estimated net profit of €401.1 million, up €44.9 million or 13% on the year before. We remain committed to the course of our long‑term growth and development as set in the adopted Krka Group development strategy for the period until 2030. Our vertically integrated business model enables us to provide for uninterrupted supplies of sufficient quantities of high-quality, safe, and effective products, and deliver on our mission Living a healthy life. The adopted strategy also served as the basis for our 2026 business plan. The plan outlines revenue from sales of products and services at €2,132 million, net profit at €405 million, and almost a 50% increase in investments on the year before. We believe that with help of our committed coworkers already counting over 13,000 across the globe we will successfully deliver on all our plans.”
Of last year’s total revenue (€2,041 million), contracts with customers on sales of products and services accounted for €2,034 million; other sources made up the remainder.
Prescription pharmaceuticals made up most sales at €1,691.7 million—an increase of 8% over 2024—and represented more than four-fifths (83%) of total group sales.
Regional analysis showed increases everywhere except Overseas Markets: East Europe grew by 12%; Central Europe and South-East Europe each rose by 8%; Slovenia increased by 6%; West Europe grew by 4%. Among major individual markets for prescription pharmaceuticals—the Russian Federation led absolute growth followed by Poland, Scandinavia and Germany; Belarus, Belgium and Portugal were among other markets showing substantial gains.
The unaudited financial statements are scheduled to be published on March 12th ,2026.
